<DOC>
	<DOCNO>NCT02155595</DOCNO>
	<brief_summary>The purpose protocol determine risk atypical femoral shaft ( thigh bone ) fracture long term fracture prevention therapy class drug call `` bisphosphonates '' , colloquially referred Alendronate , risedronate , Ibandronate , Zoledronate . In addition , study design find patient likely develop potential life change complication . Finally , result study help clinician well understand reason thus tailor patient specific treatmentsâ€¦i.e. , `` right treatment right patient right duration . ''</brief_summary>
	<brief_title>Pathogenesis Atypical Femur Fractures Long Term Bisphosphonate Therapy</brief_title>
	<detailed_description />
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Femoral Fractures</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>woman diagnosis osteopenia osteoporosis define Bone Mineral density ( BMD ) patient treat BPs &gt; 5 year patient treat nonBP antifracture medication ... estrogens , raloxifene , calcitonin treatment naive patient men regardless BMD result patient obvious traumatic AFF patient normal BMD ( well 1.0 Tscore spine proximal hip ) unable take tetracycline previous use teriparatide know allergy follow : tetracycline antibiotic meperidine midazolam</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>